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Abstract: Many patients suspect wheat as being a major trigger of their irritable bowel syndrome
(IBS) symptoms. Our aim was to evaluate whether sourdough wheat bread baked without baking
improvers and using a long dough fermentation time (>12 h), would result in lower quantities of
alpha-amylase/trypsin inhibitors (ATIs) and Fermentable, Oligo-, Di-, Mono-saccharides and Polyols
(FODMAPs), and would be better tolerated than yeast-fermented wheat bread for subjects with
IBS who have a poor subjective tolerance to wheat. The study was conducted as a randomised
double-blind controlled 7-day study (n = 26). Tetrameric ATI structures were unravelled in both
breads vs. baking flour, but the overall reduction in ATIs to their monomeric form was higher in the
sourdough bread group. Sourdough bread was also lower in FODMAPs. However, no significant
differences in gastrointestinal symptoms and markers of low-grade inflammation were found between
the study breads. There were significantly more feelings of tiredness, joint symptoms, and decreased
alertness when the participants ate the sourdough bread (p ≤ 0.03), but these results should be
interpreted with caution. Our novel finding was that sourdough baking reduces the quantities of
both ATIs and FODMAPs found in wheat. Nonetheless, the sourdough bread was not tolerated better
than the yeast-fermented bread.
Keywords: irritable bowel syndrome; wheat sensitivity; gluten sensitivity; wheat; ATI; amylase
trypsin inhibitor; FODMAP
1. Introduction
Functional gastrointestinal disorders (FGDs) are common, and irritable bowel syndrome (IBS)
is one of the most typical forms, affecting 11% of the adult population in developed countries [1].
IBS patients typically report intolerance to wheat, milk, onion, garlic, apples, alcohol, coffee, chili,
and beans [2]. Non-coeliac gluten sensitivity, also known as wheat sensitivity, has attracted attention,
both in the popular media and scientific literature [3–6]. Gluten per se has been long postulated to
cause symptoms in some IBS patients, although 86% of patients with subjective wheat tolerance do not
seem to respond to gluten pills in masked conditions [7], thus leaving the role of gluten unclear.
A randomised 7-day study concluded that gluten, in low or high doses, did not worsen symptoms
of IBS when compared to a whey protein-based placebo in low-FODMAP diet conditions [8]. Indeed,
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it has been acknowledged that it is unlikely that gluten alone is responsible for all wheat-related
symptoms [9]. FODMAPs (Fermentable, Oligo-, Di-, Mono-saccharides and Polyols), i.e., rapidly
fermented unabsorbed short-chain carbohydrates in wheat, can cause symptoms in the presence of
typical IBS-related features, such as impaired handling of intestinal gas, abnormalities in bowel motility
and visceral sensitivity [9,10]. The rapid fermentation of FODMAPs is suggested as a mechanism that
triggers IBS symptoms.
Preliminary in vitro and animal studies have indicated that amylase-trypsin inhibitors (ATIs)
and other non-gluten proteins have a pro-inflammatory effect on intestinal epithelial cells and thus
are theoretically capable of triggering gastrointestinal symptoms in humans [11–13]. However,
there have been no randomised trials investigating ATIs. In fact, there is an on-going debate as
to whether it is wheat proteins (such as ATIs and gluten) or FODMAPs that are the true triggers of
wheat-related symptoms in FGD, or if their combination through a possible synergic effect is required
for symptom aggravation.
One method of decreasing the amount of FODMAPs and possibly the bioactivity of ATIs in bread
(and thus theoretically improving its tolerability), is the utilization of prolonged fermentation processes
in breadmaking. Sourdough fermentation activates some proteolytic and fructosidase enzymes in
dough, and can thus decrease the amount of proteins and fructans in the end products [14–17].
The FODMAP content of sourdough bread can be reduced by up to 90% by utilizing a specific
sourdough system, as demonstrated in our previous study [16]. Taken together, sourdough baking
could theoretically result in wheat products with improved gastrointestinal tolerability.
Recent studies of subjective wheat sensitivity and IBS have suggested that gluten-free and
low-FODMAP diets both reduce markers of low-grade inflammation [18,19]. Furthermore, one clinical
study showed that kamut wheat, which is an ancient variant of modern wheat, has the potential to
reduce inflammatory parameters in blood, as well as other symptoms, when compared to modern
wheat [20]. Kamut wheat is lower in ATIs and FODMAPs than modern wheat [13,16].
The present study aimed to evaluate whether a sourdough wheat bread could reduce the
symptoms of subjective wheat sensitivity and low-grade inflammation in IBS patients when compared
to regular toast bread, baked with added gluten, larger amounts of baker’s yeast, and baking additives.
Therefore, these effects were compared in a randomised, double-blinded, parallel group study, while
patients were adhering to an otherwise gluten-free diet. We also aimed to specify the ATI and FODMAP
content of the two breads.
2. Materials and Methods
2.1. Subjects and Study Design
A total of 26 patients with IBS were recruited via the internet and from individuals attending
a private hospital clinic (Aava Medical Centre, Helsinki, Finland). The eligibility inclusion criteria
were as follows: (1) subjects aged 18–65 years; (2) presence of IBS, as defined by the Rome III criteria;
and (3) subjective intolerance to wheat.
The diagnosis of subjective wheat intolerance was based on the answer “yes” to the written
screening question “I often experience different symptoms when I eat foodstuffs containing wheat and
these symptoms are unpleasant”. Intolerance was confirmed by the study dietician during a telephone
interview. The headline of the recruitment advertisement was also presented as the question: “Do you
experience symptoms if you eat wheat?” We did not perform any blinded exposure tests for wheat,
or any biochemical tests, as these do not exist for the diagnosis of wheat intolerance. The exclusion
criteria included the presence of an organic gastrointestinal (GI) disease (such as inflammatory bowel
disease or celiac disease), major abdominal surgery, any malignancy, pregnancy or breastfeeding, or
use of medication potentially influencing gastrointestinal function.
Study candidates were pre-screened by a study dietician. Those subjects meeting the preliminary
inclusion criteria were subsequently referred to a screening consultation to a gastroenterologist, who
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then assessed their final eligibility for participating in the trial. Blood count, sedimentation rate,
transglutaminase antibodies for celiac disease, and thyroid function tests were performed during the
physician’s screening visit, if these tests had not already been performed within the past 12 months.
Laboratory tests were conducted to ensure that the patients were eligible to participate in this trial;
for example, all participants with elevated anti-tissue transglutaminase immunoglobulin A (IgA)
antibodies were excluded. Patients were provided with obligatory written informed consent forms,
which they all signed.
The study protocol was approved by the ethics committee of the Hospital District of Helsinki and
Uusimaa. The trial was registered at the United States (US) National Institutes of Health (ClinicalTrials.gov)
with the trial number, NCT02572908.
This study was a randomised, double blinded, parallel-group study with a 1-week run-in period,
followed by a 1-week treatment period, in which the patients received either the sourdough wheat
bread or yeast-fermented wheat bread. Subjects were advised to adhere to a gluten-free diet during
the 2-week study duration, the details of which were described to participants by the study dietician.
A gluten-free diet was recommended, in order to eliminate any potential confounding, attributable to
other gluten-containing grains. The participants were asked to keep 3-day food records during the
run-in and treatment period. Randomisation was performed in blocks of four, with a non-concealed
allocation. Our statistician generated the computer-assisted randomisation list. The randomisation
was blinded for both the participants and the investigators.
2.2. Study Breads
The breads were manufactured by Fazer Bakeries (Vantaa, Finland). Both test breads were made
using the same baker’s wheat flour (Fazer Mills, Lahti, Finland). The yeast-fermented bread was
prepared in an industrial scale bakery, using a straight-dough bread making process that lasted
approximately 2 h (including dough mixing, dough rest, moulding, proofing, and oven baking).
The recipe of yeast-fermented bread contained added wheat gluten (2% of flour weight), bread
improvers (such as emulsifiers), and sorbic acid (E200) as a preservative. The sourdough bread was
produced in pilot scale, using a dough mixer and moulded by hand. The sourdough bread used wheat
sourdough in the recipe with a long bulk fermentation stage. Overall, the dough stage took more than
12 h. No improvers or any added gluten or preservatives were used in the sourdough bread recipe.
The breads were packaged in white plastic pouches so that participants could not compare the
appearance of the study breads (Supplementary Materials Figure S1). The nutrient composition was
analysed by Eurofins Scientific Finland (Food & Agro, Raisio, Finland). The dietary fibre content of the
breads was determined by using the American Association of Analytical Chemists (AOAC) 2011.25
method [21], a procedure that can discriminate between soluble and insoluble as well as between low
and high molecular weight dietary fibres. Resistant starch was identified using the AOAC 2002.02
method [22]. The fructan content was measured by using the AOAC 999.03 method [23] (Megazyme
assay kit K-FRUC, Megazyme International Ireland Ltd., Bray, Ireland). The nutritional composition of
the study breads is presented in Table 1. The fructan content of sourdough bread represented more
than a quarter (26%) of the fructan content of yeast-fermented bread, whereas the protein content was
almost the same (94%) as in yeast-fermented wheat bread.
Patients were advised to consume 150 g (six slices) of the study breads every day. Adherence to
bread consumption was evaluated by patient entries into a tick-box diary for the treatment period and
also by food records.
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Table 1. Nutritional composition of the study breads.
Sourdough Bread */100 g Yeast-Fermented Bread */100 g
Energy, kJ (kcal) 972 (229) 1116 (264)
Protein, g 9.3 9.9
Gluten, g 4.8 6.0
Fat, g 1.2 2.4
Carbohydrates, g 43.4 48.4
Dietary fibre, g 3.9 4.5
Salt, g 1.2 1.1
Fructans, g 0.06 0.23
LMWDF, g 0.9 1.0
Insoluble HMWDF, g 1.8 2
Soluble HMWDF, g 1.2 1.4
Resistant starch, g 0.7 0.8
Dominant ATI form Monomeric Dimeric
Additives/Improvers Not present Present
LMWDF: Low molecular weight dietary fibre; HMWDF: High molecular weight dietary fibre; ATI:
alpha-amylase/trypsin inhibitor. * Participants were supplied with and instructed to consume 150 grams of
each bread/day.
2.3. Determination of Monomeric, Dimeric and Tetrameric ATIs
Sourdough bread and yeast-fermented bread were cut into small pieces, excluding the crusts.
Albumins were extracted from 1 g of bread and flour samples, using a 20 mL buffer, containing 10 mM
Tris-HCl and 0.1 M ethylenediaminetetraacetic acid (EDTA), with pH 7.5 at 4 ◦C for 1 h, with gentle
shaking. Following centrifugation at 10,000× g at 4 ◦C, the supernatant was collected and precipitated
with 50% ammonium sulphate at room temperature. The precipitates were dissolved in the same
buffer and its protein concentration was determined by a detergent compatible (DC) protein assay
Kit (5000111, Bio-Rad Laboratories Inc., Hercules, CA, USA) with a bovine serum albumin standard.
The protein concentration of albumins from sourdough bread, yeast-fermented bread, and flour were
adjusted to the same level. The albumin composition was analysed by SDS-PAGE with 12% Bis-Tris
protein gel (NP0341BOX, ThermoFisher Scientific, Waltham, MA, USA). The albumin solutions were
mixed with a lithium dodecyl sulfate (LDS) sample buffer (NP0008, ThermoFisher Scientific, Waltham,
MA, USA), and with or without sample-reducing agent (NP0009, ThermoFisher Scientific, Waltham,
MA, USA), and then boiled for 3 min. The running buffer was 3-Morpholinopropane-1-sulfonic
acid (MOPS, NP0001), and the protein standard was SeeBlue Plus2 (LC5925, ThermoFisher Scientific,
Waltham, MA, USA). The applied voltage was 200 V, and the run time was 50 min. The gel was stained
with Coomassie R-250 brilliant blue. The monomer, dimer, and tetramer forms of ATI were recognised
according to their molecular weights [24].
2.4. Inflammatory Markers
Inflammatory biomarkers, interleukin 8 (IL-8), interleukin 6 (IL-6) and lipopolysaccharide binding
protein (LBP), were measured at baseline and after the treatment period with study breads. Serum IL-6
(BMS213HS, ThermoFisher Scientific, Waltham, MA USA), IL-8 (HS800, R&D Systems, Abingdon, UK)
and LBP (HK315-01, LBP; Hycult Biotech, Uden, The Netherlands) levels were quantified using
sensitive enzyme-linked immunosorbent assays (ELISA).
2.5. Symptoms
We constructed a questionnaire based on visual analogue scales (VAS 0–100 mm) to assess
the severity of gastrointestinal symptoms and the other symptoms which could be related to IBS.
Gastrointestinal symptoms were flatulence, bloating, diarrhoea, constipation, abdominal pain and
cramps, borgorygmia, heartburn, nausea, dyspepsia, feeling of incomplete defecation, and urgency in
defecation. Other symptoms were tiredness, joint symptoms, skin rash, decreased alertness, and loss of
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appetite. We did not formally validate the questionnaire with respect to the 17 different symptoms but
it follows the practice and concept described by Francis et al. [25] and has been used previously [7,8,17].
2.6. Statistical Analysis
No sample size calculations were performed because of the pilot nature of the study and because
no benchmark studies existed at the time of the initiation of the study. The patient characteristics
are expressed as medians (range) for continuous variables and as number of patients (%) for
categorical variables.
Dietary intakes were measured during the run-in period and during the study breads.
The Mann–Whitney U test was used to compare the study groups with respect to dietary intakes.
The number of consumed slices of study breads was assessed every day during the treatment period.
The Mann–Whitney U test was used to compare the average number of consumed slices of study
breads. Dietary intakes are expressed as medians (inter-quartile range), due to skewed distributions.
In regard to inflammatory markers, the study breads were compared using an analysis of covariance
(ANCOVA), where the baseline was included as a covariate. The distributions of IL-8 and IL-6 were
skewed to the right and were logarithmically (ln) transformed before analysis. Due to logarithmic
transformation, the comparisons are given as ratios of sourdough bread/yeast-fermented bread.
Gastrointestinal symptoms and the other symptoms were measured daily using VAS (0–100 mm)
during the 7-day run-in period and during the 7-day treatment period with study breads. The run-in
period was considered the baseline. The symptom scores (mean of weekly measurements) for all
symptoms were calculated for baseline and for the treatment period. The total symptom scores were
calculated for gastrointestinal symptoms (mean of 12 symptoms) and for other symptoms (mean
of five symptoms). Analysis of covariance (ANCOVA) was used when the symptom scores were
compared between the study breads and the symptom score during the baseline was included as a
continuous covariate. The differences between study breads (sourdough bread vs. yeast-fermented
bread) are given as baseline-adjusted means with 95% confidence intervals. The total score for the
12 gastrointestinal symptoms (gastrointestinal total score in Table 5) was the primary outcome variable
and the total score for the five other symptoms (other symptoms total score in Table 6) was the key
secondary variable. Other secondary outcome variables included the 12 gastrointestinal symptoms
and 5 other symptoms, each individually, and the three inflammatory markers. No adjustment of
p-values for multiple testing was performed for the secondary outcome variables. This is an unpowered
exploratory pilot study and p-values should not be over-interpreted. Therefore, adjustment of p-values
was not appropriate.
The statistical analysis was performed using IBM SPSS Statistics for Windows (versions 22.0 and
23.0, IBM Corp, Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics
In total, 26 subjects with IBS were recruited into the study and none withdrew during its duration.
Table 2 depicts the characteristics of the subjects and Supplementary Materials Figure S2, the flow
chart. All subjects, except one, were female (96%). Their median age was 43 (range 21–64) years and
median body mass index was 25.0 (range 19.6–37.7) kg/m2. Four subjects (15%) reported minor use
of wheat bread even though it evoked some subjective symptoms, and all of them were randomly
assigned into the yeast-fermented bread group. More than half of the subjects (58%) reported following
a gluten-free diet before study entry: 6/13 subjects in the sourdough and 9/13 in the yeast-fermented
group. The rest reported tolerating wheat in minimal amounts occasionally.
Nutrients 2017, 9, 1215 6 of 16
Table 2. Baseline characteristics of the participants.
Characteristics Sourdough Bread(n = 13)
Yeast-Fermented Bread
(n = 13)
Total
(n = 26)
Females 12 (92) 13 (100) 25 (96)
Age (years) 39 (21–56) 47 (24–64) 43 (21–64)
Body mass index, BMI (kg/m2) 25.1 (20.2–37.7) 24.9 (19.6–31.8) 25.0 (19.6–37.7)
Weight (kg) 70 (59–109) 65 (54–92) 68 (54–109)
Self-reported daily consumption of
any bread (number of slices) 3.0 (1–4) 2.5 (1–7.5) 3.0 (1–7.5)
Occasional use of some wheat bread 0 (0) 4 (31) 4 (15)
Results are given as median (range) and as n (%) of subjects.
3.2. Dietary Intakes
Dietary intakes are reported in Table 3. Consumption of the study breads did not cause any
statistically significant differences in the subjects’ energy intakes. Furthermore, there were no
statistically significant differences in the intakes of fibre, carbohydrates, fat, or protein between
the breads, even although the median fat intake between sourdough bread vs. yeast-fermented bread
appeared to differ (79 g vs. 70 grams; p = 0.34). The changes in dietary intakes from baseline were also
non-significant between study breads (data not shown).
The median (IQR) intake of fructans from the breads was 0.08 (0.07–0.09) g/day with the
sourdough wheat bread. This was significantly less than for the yeast-fermented bread, which yielded
a value of 0.31 (0.24–0.3) g/day (p < 0.001). There was no significant difference in the median number
of bread slices consumed per day, i.e., 5.6 (139 g) for the sourdough bread and 5.4 (136 g) for its
yeast-fermented counterpart (p = 0.92).
Table 3. Dietary intake during the baseline and during consumption of the study breads.
Sourdough Bread
(n = 13)
Yeast-Fermented Bread
(n = 13) p-Value *
Energy, kJ/day Baseline 8422 (7521–9530) 8177 (7062–8425) 0.80Study bread 8214 (7826–8558) 7609 (6498–9899)
Energy, kcal/day Baseline 2012 (1797–2276) 1953 (1687–2012) 0.84Study bread 1962 (1869–2044) 1818 (1553–2365)
Carbohydrates, g/day Baseline 196 (147–236) 182 (161–215) 0.88Study bread 198 (169–221) 181 (166–281)
Protein, g/day Baseline 88 (64–103) 78 (64–102) 0.36Study bread 89 (85–107) 85 (64–107)
Fat, g/day Baseline 89 (66–103) 73 (69–88) 0.34Study bread 79 (78–86) 70 (53–83)
Dietary fibre, g/day Baseline 20 (15–22) 16 (14–22) 0.36Study bread 20 (17–22) 16 (15–24)
Results are given as median (inter-quartile range). * Dietary intakes during study breads and also the changes
from baseline were compared between the study breads with the Mann–Whitney U test. p-values for changes from
baseline varied between 0.13 and 0.96.
3.3. ATIs in the Supplied Breads
Both bread samples showed fewer albumin bands than the flour sample, although the protein
concentration was the same (Figure 1). The forms of ATI were identified on the basis of their molecular
weight [24]. The band intensity of the tetrameric ATIs decreased in the order: flour > yeast-fermented
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bread > sourdough bread (Figure 1). The dimeric ATI bands in the flour sample were not the same as
in the bread samples, and the intensity of these bands in the yeast-fermented bread was higher than in
the sourdough bread (Figure 1). The intensity of the monomeric ATI bands decreased in the order:
flour > sourdough bread > yeast-fermented bread (Figure 1). These results indicate that compared
with the yeast-fermented bread, in the sourdough-fermented bread, the ATIs possibly unravelled from
a tetrameric and dimeric form to a monomeric form, more intensively.Nutrients 2017, 9, 1215    7 of 16 
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Figure 1. SDS-PAGE of albumins from bread and flour. Lanes 1 d 8: prot in molecular weight
standard; lanes 2 and 3: albumin extract from sourdough bread; lanes 4 and 5: albumin extract from
yeast-fermented bread; lanes 6 and 7: albumin extract from wheat flour. For lanes 2, 4, and 6, marked
‘+’, samples were re uced with dithiothreitol, and those marked ‘−’ were without a reduction. Arrows
indicate α-amylase/trypsin inhibitors (ATIs) in different forms, monomer in lane 2, dimer in lane 4
and tetramer in lane 6. kDa: kilodalton.
3.4. Inflammatory Markers
We did not find significant differences between the study breads in the inflammatory markers
(Table 4). Furthe more, the change i inflammatory marker from baseline t the nd of treatment
period were not significant.
Table 4. Interleukin-8 (IL-8; pg/mL), interleukin-6 (IL-6; pg/mL) and lipopolysaccharide binding
protein (LBP; µg/mL) at baseline and after the treatment periods with study breads. Confidence
intervals (CI) are in parentheses.
Sourdough Bread
(n = 12)
Yeast-Fermented Bre d
(n = 12)
Sourdough Bread vs.
Yeast-Fermented Bread
Baseline Study Bread Baseline Study Bread
Baseline-Adjusted Difference
Ratio (95% CI) p-Value *
IL-8 (pg/mL) 11.6 (9.8–13.8) 11.2 (10.1–12.4) 13.7 (11.0–17.0) 13.3 (10.5–16.9) 0.91 (0.73 to 1.14) 0.38
IL-6 (pg/mL) 0.67 (0.34–1.32) 0.72 (0.42–1.21) 1.22 (0.78–1.90) 1.09 (0.73–1.64) 1.01 (0.74 to 1.39) 0.38
Mean (95% CI) p-Value
LBP (µg/mL) 8.39 (5.16–11.62) 8.48 (5.09–11.88) 8.15 (6.45–9.85) 9.42 (7.15–11.70) −1.19 (−2.55 to 0.17) 0.08
Results are given as geometric means (95% CI) for IL-8 and IL-6 and as the arithmetic mean (95% CI) for LBP.
* The study breads were compared using an analysis of covariance (ANCOVA), where baseline was included as a
covariate. IL-8 and IL-6 were logarithmically (ln) transformed before the analysis.
Nutrients 2017, 9, 1215 8 of 16
3.5. Symptoms
VAS measurements of gastrointestinal symptoms did not reveal any statistically significant
differences between the breads, when the weekly means were analysed (Table 5). However, tiredness,
joint symptoms, and decreased alertness were more intense when the subjects were eating the
sourdough bread (Table 6, p-values: 0.01, 0.03 and 0.003, respectively). There was no significant
difference between the breads in terms of the total gastrointestinal symptom score (i.e., the mean
of 12 symptoms) which was 27 (Standard deviation, SD 12) mm for the sourdough bread vs. 23
(SD 11) mm for the yeast-fermented bread. The baseline-adjusted difference between breads was 4
(95% CI: −4 to 11) mm, p = 0.33. There was a significant difference between the breads for the total
non-gastrointestinal score, i.e., in other symptoms, the mean of five symptoms was 26 (SD 18) mm
for the sourdough bread vs. 11 (SD 10) mm for the yeast-fermented bread. The baseline-adjusted
difference between breads was 8 (95% CI: 2 to 14) mm, p = 0.02. The development of the symptoms
during both the run-in period (days 1–7) and the treatment period (days 8–14) is illustrated in Figure 2
and in Appendix A (Figure A1a,b and Figure A2).
Table 5. Gastrointestinal symptoms (visual analogue scales, VAS 0–100 mm) and gastrointestinal total
score during the baseline (mean of days 1–7) and during consumption of the study breads (mean of
days 8–14).
Symptom
Sourdough Bread
(n = 13)
Yeast-Fermented Bread
(n = 13)
Sourdough Bread vs.
Yeast-Fermented Bread
Baseline Study Bread Baseline Study Bread Baseline-AdjustedDifference p-Value *
Flatulence 25 (16) 37 (20) 22 (12) 32 (17) 3 (−11 to 17) 0.66
Bloating 23 (17) 38 (16) 23 (15) 38 (20) 1 (−13 to 15) 0.93
Diarrhoea 10 (8) 13 (15) 12 (10) 13 (10) 1 (−9 to 10) 0.90
Constipation 16 (13) 22 (17) 14 (13) 24 (20) −4 (−16 to 8) 0.54
Abdominal pain 16 (14) 32 (15) 20 (15) 29 (15) 4 (−7 to 15) 0.44
Abdominal cramps 12 (17) 27 (19) 10 (10) 16 (13) 10 (−1 to 21) 0.06
Borgorygmia 20 (20) 34 (24) 19 (12) 23 (13) 10 (−1 to 21) 0.07
Heartburn 13 (16) 18 (16) 9 (7) 12 (10) 3 (−5 to 12) 0.43
Dyspepsia 14 (14) 29 (17) 18 (17) 24 (23) 8 (−6 to 22) 0.25
Feeling of incomplete
defecation 30 (25) 37 (25) 24 (16) 32 (24) −1 (−14 to 13) 0.93
Urgent need for defecation 18 (14) 21 (19) 20 (15) 21 (16) 1 (−10 to 12) 0.90
Nausea 12 (17) 21 (15) 10 (16) 15 (16) 5 (−4 to 13) 0.29
Gastrointestinal total score 17 (12) 27 (12) 17 (9) 23 (11) 4 (−4 to 11) 0.33
Results are given as mean (SD) and mean (95% CI). * The study breads were compared using the analysis of
covariance (ANCOVA), where the symptom score during the baseline was included as a covariate.
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Table 6. Other symptoms (VAS 0–100 mm) and other symptoms total score during the baseline (mean
of days 1–7) and during the consumption of the study breads (mean of days 8–14).
Symptom
Sourdough Bread
(n = 13)
Yeast-Fermented Bread
(n = 13)
Sourdough Bread vs.
Yeast-Fermented Bread
Baseline Study Bread Baseline Study Bread Baseline-AdjustedDifference p-Value *
Tiredness 30 (24) 40 (25) 17 (15) 14 (15) 16 (4 to 27) 0.01
Joint symptoms 17 (19) 23 (21) 9 (14) 7 (13) 7 (1 to 13) 0.03
Skin rash 11 (18) 14 (18) 3.5 (3) 5 (5) 3 (−5 to 11) 0.45
Decreased alertness 22 (25) 35 (26) 12 (15) 13 (12) 14 (5 to 22) 0.003
Loss of appetite 12 (18) 19 (15) 9 (12) 15 (15) 2 (−6 to 9) 0.62
Other symptoms total score 19 (17) 26 (18) 10 (11) 11 (10) 8 (2 to 14) 0.02
Results are given as mean (SD) and mean (95% CI). * The study breads were compared using the analysis of
covariance (ANCOVA), where the symptom score during the baseline was included as a covariate.
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Figure 2. The development of total scores for gastrointestinal sy pto s (VAS 0–100 m) over the
course of the study. Days 1–7 (strict gluten free diet) are considered as baseline and days 8–14 as the
actual treatment period with study breads. Circles with error bars indicate means (standard error of
mean, SEM).
4. Discussion
Our study provides some novel findings. As far as we know, we have demonstrated for the first
time that ATI profiles of sourdough and yeast-fermented bread may differ. The molecular weights
of the ATIs in this study are in agreement with published values of 60 kDa for tetramers, 24 kDa for
dimers, and 12 kDa for monomers [24]. The lower content of ATI polymers (molec lar weight >14 kDa)
in the sourdough bread than in the yeast-fermented bread is likely attributable to the more intensive
reduction during sour ough fermentation, as hown by the greater intensity of the monomeric ATI
bands in the sourdough lanes. Reduc d ATIs per se have been reported to have less stimulatory
activity agai st toll-like-receptor 4 (TLR4), and thu c use less innate immune reactions, in vitro and
in animals [11,13], but no clinical trials had been performed on ATIs prior to our study.
As far as we know, this is the first study to show that sourdough baking apparently more
extensively unravels the tetrameric and dimeric form of ATIs when compared to yeast-fermented
bread/wheat flour. This may be due to disulphide bond reduction, as sourdough redox conditions
are known to be reductive [26]. The remaining ATIs in sourdough bread had weights of
approximately 12 kDa, and thus were likely members of the ATI species, chloroform-methanolsoluble
(CM) 0.28 [27]. ATIs of the CM 0.28 family do not have an especially pro-inflammatory effect in the
gastrointestinal tract [11,13]. The sourdough bread was also absent of baking improvers (additives),
when compared to yeast-fermented bread. Despite being lower in ATIs, fructans, and additives,
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the sourdough bread caused a rapid increase in many symptoms, and was not tolerated better than the
yeast-fermented bread. This was in contrast to our hypothesis; the sourdough bread actually caused more
non-gastrointestinal symptoms. We believe that the observed difference in non-gastrointestinal symptoms
between the groups is likely to be due to chance, or due to a slight difference between the study groups
at baseline (see discussion below). Theoretically, it is possible, albeit unlikely, that some unrecognized
factor, such as metabolites in sourdough bread, might have caused the observed difference. The small
sample size is a limitation of our study, and needs to be considered in this context. Our symptom
evaluation was based on VAS measurements, which are not validated by dietary IBS studies, even if
they are widely used. Clearly, further research is warranted to confirm the pilot results reported herein.
Secondly, we demonstrated that the consumption of 5.4–5.6 slices of the wheat breads daily,
as a sole source of wheat, did not increase inflammatory markers of innate immune activation, even
though symptoms worsened rapidly. Therefore, the observed rapid worsening of symptoms, especially
in sourdough bread, is unlikely to be caused by pro-inflammatory effects of wheat in the intestine.
On the contrary, we argue that the major driver of the symptoms was the nocebo effect; participants
may have expected adverse effects to any kind of wheat products, due to previous experiences and/or
beliefs. Alternatively, both wheat breads per se might have caused gastrointestinal symptoms by
forming a bolus in stomach, inhibiting gastric emptying, and reducing small bowel water, as a magnetic
resonance imaging (MRI) study with whole wheat bread has suggested [28].
Seven days may be too short of a time period to detect changes in inflammatory markers, although
previous experimental findings have suggested that pro-inflammatory reactions to wheat can be
rapid [13,29]. Our first clinical results related to ATIs and markers of innate immunity urge the need
for further studies, in order to clarify the effects of wheat products—such as bread and pasta—on
innate immunity. It would be of interest to compare ATI profiles of sourdough wheat bread, wheat
pasta and wheat flour. One would assume that pasta is higher in intact ATIs than sourdough bread,
as it is not exposed to the fermentation process in food manufacturing. On the other hand, pasta is
cooked in hot water and rinsed with water after cooking, which may remove a remarkable proportion
of ATIs, as they are water-soluble albumin proteins.
Finally, the FODMAP content of our sourdough wheat bread was reduced by 74%, as compared
to yeast-fermented bread (fructans 0.23 g/100 g), making our sourdough wheat bread clearly lower in
fructans (0.06 g/100 g) than rice cakes or rice bubbles [30]. Rice is known to be very low in fructans
and well tolerated. Consequently, the remaining FODMAPs in sourdough wheat bread are unlikely
triggers of symptoms unless bread is eaten in extreme portions per sitting. We also hasten to add that
our results should not be interpreted as a critique against holistic low-FODMAP diets in the treatment
of IBS, simply because the achieved daily reduction of intake of fructans was likely too small in
total. The achieved difference in the FODMAP intake due to the breads was approximately 0.3 g/day,
and such a difference represents just 20% of what has been shown to be a minimal meaningful
difference, i.e., 1.5 g/day [17]. Even if we did not expect the difference in FODMAPs in the breads to
play a major role, we hypothesized that the synergic effect of several potentially beneficial changes
might play a role; after all, sourdough bread was found to have a lower content of FODMAPs, ATIs,
gluten, and additives. Furthermore, it also seems that the yeast-fermented bread we used in our
study was lower in FODMAPs than those that are marketed elsewhere, i.e., 0.23 g/100 g in our study
compared to 0.68 g/100 g in Biesiekierski’s Australian study [30].
Our study has some limitations. As no clinical ATI studies were available at the time of the
initiation of the study, we did not perform power calculations. A slight difference between the groups
in the tolerance of wheat at baseline (Table 2) might have caused some bias into symptoms, favouring
yeast-fermented bread; nevertheless, no differences were seen in the inflammatory markers at baseline,
nor after the treatments, suggesting that any potentially existing bias was marginal. Finally, we did
not compare in vitro inflammatory responses to ATIs of our study products and therefore were unable
to quantify the theoretic inflammatory potential of the wheat products used—we are considering this
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in the future, in order to confirm our novel findings. Moreover, ATIs observed in this study were not
identified by sequencing or immunological methods and must thus be considered likely ATIs.
A crossover design might have been a more appropriate choice for the purpose of this study, rather
than the parallel group design. However, there were two reasons we did not want to run a crossover
study. Firstly, we considered that many patients might drop out from the study if they had to expose
to themselves to a substantial amount gluten/wheat breads (approximately 150 g/day) during the
separate periods, as they would have in a crossover design. Furthermore, the sourdough wheat bread
and yeast-fermented wheat bread had different physical appearances (supplemental image). If all
participants had been exposed to both breads, the key strength of our study—blinding—might have
been lost. Participants might have guessed by appearance, which bread was sourdough, and which
one was yeast-fermented. For these reasons we chose a parallel design. We emphasise that our pilot
results must be considered a preliminary effort, paving the way for larger studies, and we recognise
that the number of participants in our study was low for a parallel group design.
5. Conclusions
In conclusion, our pilot study did not reveal any significant differences in gastrointestinal
tolerability or in low-grade inflammation when comparing sourdough wheat bread and
yeast-fermented wheat bread, in subjects with irritable bowel syndrome/poor tolerance to wheat.
Our findings, together with those of recent clinical trials on wheat sensitivity [31], underline the need
for larger-scale clinical studies. Data from in vitro and animal studies cannot be extrapolated into
clinical care and as such randomised studies are needed to verify pre-clinical outcomes. Furthermore,
our study also highlights the fact that ATI analyses of wheat flour or other unfermented wheat
products, cannot be extrapolated to fermented wheat products, such as sourdough bread. More studies
with longer treatment periods and larger sample sizes are required to further clarify the role of ATIs
and grain products as such in functional gastrointestinal disorders. The nocebo response seems to
play a major role in IBS and subjective wheat sensitivity, and might explain our findings regarding
non-gastrointestinal symptoms. The nocebo effect should be carefully addressed when planning
future studies.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/11/1215/s1,
Figure S1: Flow chart, Figure S2: Pouched study breads.
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Figure A1.  The  development  of  gastrointestinal  symptoms  (VAS  0–100 mm)  over  the  course  of 
study. Days 1–7 (strict gluten free diet) are considered as the baseline and days 8–14 as the actual 
treatment period with study breads. Circles with error bars  indicate means (SEM). The symptoms 
are (a) flatulence, bloating, diarrhea, constipation, abdominal pain and abdominal cramps, and (b) 
borgorygmia,  heartburn, dyspepsia,  feeling  of  incomplete defecation,  urgent  need  for  defecation 
and nausea. 
Figure A1. The development of gastrointestinal symptoms (VAS 0–100 mm) over the course of study.
Days 1–7 (strict gluten free diet) are considered as the baseline and days 8–14 as the actual treatment
period with study breads. Circles with error bars indicate means (SEM). The symptoms are (a) flatulence,
bloating, diarrhea, constipation, abdominal pain and abdominal cramps, and (b) borgorygmia,
heartburn, dyspepsia, feeling of incomplete defecation, urgent need for defecation and nausea.
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